Genetic testing for beta thalassemia
Part of Blood & lymphatic clinical trials.
This study looks for a specific genetic change (in the KLF1 gene) in people with beta thalassemia. If found, it might help explain how the disease runs in families.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with beta thalassemia (major or intermedia)
- Any age or gender
- No other types of hemolytic anemia (like sickle cell)
- Not currently taking hydroxyurea
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the activity of a gene called EKLF in people with beta-thalassemia, a blood disorder that causes low hemoglobin and anemia. By measuring this gene, researchers hope to better understand the condition and find ways to improve treatment.
This trial tests a new gene therapy for beta thalassemia. A modified virus is used to deliver a working gene to your blood stem cells, which may help your body produce normal hemoglobin and reduce the need for blood transfusions.
This trial tests a one-time gene therapy using your own stem cells to help you produce healthy red blood cells and reduce or eliminate the need for regular blood transfusions. It is for people with transfusion-dependent beta-thalassemia who are between 3 and 35 years old.
This trial tests a new gene therapy for people with beta-thalassemia who need regular blood transfusions. It uses a virus to deliver a working gene into your own stem cells, then those cells are put back into your body to help your body make healthy red blood cells.
This study tests an experimental gene-editing treatment called CS-101 for people with severe beta-thalassemia who need regular blood transfusions. The goal is to see if it can reduce or eliminate the need for transfusions by helping the body make more healthy red blood cells.
This early study tests the safety and potential benefit of the LentiRed gene-based drug in people with transfusion-dependent beta-thalassemia (TDT) who are planning an autologous stem cell transplant. It may help reduce the severity of anemia, but the main goal at this stage is to check safety and side effects.
Hear when a new EKLF Mutations in Beta Thalassemia Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.